ISRCTN75807641 https://doi.org/10.1186/ISRCTN75807641

Telmisartan randomised assessment study in ACE intolerant subjects with cardiovascular disease

Submission date 18/12/2002	**Recruitment status** No longer recruiting	[X] Prospectively registered [X] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 18/12/2002	**Overall study status** Completed	
Last Edited 21/03/2016	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Salim Yusuf

Contact details
Population Health Research Institute
McMaster University
Hamilton General Hospital
McMaster Clinic
237 Barton St E
Hamilton
Canada
Ontario L8L 2X2
+1 (0)905 527 4322 ext 44515
yusufs@mcmaster.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00153101

Secondary identifying numbers
N/A

Study information

Scientific Title
Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

Acronym
TRANSCEND

Study objectives
This parallel trial to ISRCTN16228603 (ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial = ONTARGET) is to determine in angiotensin converting enzyme inhibitor (ACE-I) intolerant patients if telmisartan 80 mg daily is superior to placebo in reducing the composite endpoint of cardiovascular death, myocardial infacrtion (MI), stroke or hospitalisation for congestive heart failure (CHF).

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Congestive heart failure

Interventions

Telmisartan (an angiotensin II blocker) or matched placebo.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Telmisartan

Primary outcome measure
1. Cardiovascular death
2. Non-fatal myocardial infarction
3. Non-fatal stroke
4. Hospitalisation for congestive heart failure

Secondary outcome measures
1. Newly diagnosed congestive heart failure
2. Cardiovascular revascularisation procedures
3. Newly diagnosed diabetes
4. Cognitive decline (adjudication will be done by a special committee)
5. New onset of atrial fibrillation
6. Nephropathy

Overall study start date
01/01/2004

Completion date
01/01/2008

Eligibility

Key inclusion criteria
1. Adults greater than or equal to 55 years
2. With a history of symptomatic coronary artery disease, cerebrovascular disease, peripheral vascular disease, or diabetes mellitus
3. Without proteinuria
4. Who are intolerant of ACE inhibitors

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants

6000

Key exclusion criteria
Does not comply with the above criteria

Date of first enrolment
01/01/2004

Date of final enrolment
01/01/2008

Locations

Countries of recruitment
Australia

Austria

Belgium

Canada

China

Czech Republic

Denmark

Finland

France

Germany

Greece

Hong Kong

Hungary

Ireland

Italy

Korea, South

Malaysia

Mexico

Netherlands

New Zealand

Norway

Philippines

Poland

Portugal

Puerto Rico

Russian Federation

Singapore

Slovakia

South Africa

Spain

Sweden

Switzerland

Taiwan

Thailand

Türkiye

Ukraine

United Arab Emirates

United Kingdom

United States of America

Study participating centre
Hamilton General Hospital
Hamilton
Canada
Ontario L8L 2X2

Sponsor information

Organisation
Boehringer Ingelheim (Canada) Ltd

Sponsor details
Research and Development
2100 Cunard Street
Laval (Québec)
Canada
H7S 2G5
+1 (0)450 682 4640
info@lav.boehringer-ingelheim.com

Sponsor type
Industry

Website
http://www.boehringer-ingelheim.ca/

ROR
https://ror.org/031sxg258

Funder(s)

Funder type
Industry

Funder Name
Boehringer Ingelheim (Canada) Ltd

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No

Protocol article	protocol	01/07/2004	Yes	No
Other publications	baseline data	01/04/2005	Yes	No
Results article	results	20/03/2007	Yes	No
Results article	results	27/09/2008	Yes	No
Results article	results	06/10/2009	Yes	No
Results article	results	30/03/2010	Yes	No